Glucagon-like peptide-1 receptor agonists, also known as GLP-1 analogs, GLP-1RAs, or incretin mimetics, are a class of anorectic drugs that reduce blood sugar and energy intake by activating the GLP-1 receptor. From Wikipedia
NIH-funded research shows a modest reduction in obesity-related cancer risk and all-cause mortality among diabetic adults using GLP-1 receptor agonists, with notable benefits for women.
